| Drug Name |
Fexofenadine |
| Drug ID |
BADD_D00893 |
| Description |
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms.[L4269] It is selective for the H1 receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation.[A1452] Fexofenadine is the major active metabolite of [terfenadine][A1495] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.[L10779] |
| Indications and Usage |
In the United States, fexofenadine is indicated for the symptomatic treatment of allergic rhinitis in patients ≥2 years old and chronic idiopathic urticaria in patients ≥6 months old.[L4269] In Canada, fexofenadine carries the same indications but is approved only for patients ≥12 years old.[L10779] Fexofenadine is also available in combination with [pseudoephedrine] for the symptomatic treatment of season allergic rhinitis in patients ≥12 years old.[L10800] |
| Marketing Status |
approved; investigational |
| ATC Code |
R06AX26 |
| DrugBank ID |
DB00950
|
| KEGG ID |
D07958
|
| MeSH ID |
C093230
|
| PubChem ID |
3348
|
| TTD Drug ID |
D01KPV
|
| NDC Product Code |
Not Available |
| UNII |
E6582LOH6V
|
| Synonyms |
fexofenadine | alpha-(4-(1-carboxy-1-methylethyl)phenyl)-4-hydroxydiphenylmethyl-1-piperidinebutanol | fexofenadine hydrochloride | MDL 16.455 | MDL-16455 | MDL 16455 | Allegra | Telfast | MDL 16,455A |
